Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICD Medicare Coverage Expansion Unwarranted, Insurance Group Contends

This article was originally published in The Gray Sheet

Executive Summary

America's Health Insurance Plans' efforts to dissuade CMS from expanding ICD national coverage until more conclusive evidence becomes available reflects the insurance industry's insistence on evidence-based medicine to justify expensive technologies

You may also be interested in...



ICD Benefits Roughly Equal For Ischemics, Non-Ischemics – JAMA Study

Implantable cardioverter defibrillators are associated with roughly the same relative benefit over medical therapy in both non-ischemic and ischemic cardiomyopathy patients, according to a meta-analysis by Akshay Desai, MD, Brigham and Women's Hospital, et al.

ICD Benefits Roughly Equal For Ischemics, Non-Ischemics – JAMA Study

Implantable cardioverter defibrillators are associated with roughly the same relative benefit over medical therapy in both non-ischemic and ischemic cardiomyopathy patients, according to a meta-analysis by Akshay Desai, MD, Brigham and Women's Hospital, et al.

National ICD Registry Proposal Critiqued By Manufacturers, ACC/HRS

CMS' implantable cardioverter defibrillator registry should limit its initial scope to follow-up data at the time of re-hospitalization to keep expenses manageable, according to ICD manufacturers and professional societies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel